Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
about the author
Max Bayer
Pharma Reporter
mbayer@endpointsnews.com
author articles
CDC advisors decline to recommend RSV shots to younger at-risk adults, affirming prior guidance
7 months ago
Pharma
FDA+
Icon's quarterly earnings hit by biotech and pharma pullback
7 months ago
R&D
Outsourcing
Adults 50 and up should get pneumococcal vaccine, CDC advisors say, in boost to Pfizer and Merck
7 months ago
Pharma
FDA+
Pfizer wins approval to expand RSV vaccine to adults at higher infection risk
7 months ago
Pharma
FDA+
Starboard's Kenvue complaints are much different than those aimed at Pfizer
7 months ago
Pharma
Updated: Pfizer's activist says board must 'hold management accountable' for R&D shortcomings
7 months ago
Pharma
Starboard takes activist stake in J&J consumer spinout Kenvue
7 months ago
Pharma
Vertex shares full pivotal non-opioid pain data, showing better safety than placebo
7 months ago
R&D
Lykos is optimistic about MDMA treatment after meeting with FDA
7 months ago
R&D
Pharma
Pfizer’s RSV vaccine has 90% efficacy against severe respiratory disease
7 months ago
Pharma
Bavarian Nordic's mpox vaccine was safe and spurred promising immune response in children
7 months ago
R&D
Pharma
Facing a critical week, Pfizer confronts an unsparing foe in Starboard
7 months ago
Pharma
J&J’s medtech slump continues, improvements not expected until 2025
7 months ago
Pharma
J&J trims pipeline, including two mid-stage neuroscience studies
7 months ago
R&D
Pharma
Sanofi lands on private equity firm CD&R as potential buyer of consumer health unit
7 months ago
Deals
Pharma
Sanofi discontinues Denali-partnered MS trial after Phase 2 failure
7 months ago
R&D
Exclusive: How an accidental email tipped Pfizer off to an activist investor’s plan
7 months ago
People
Pharma
Starboard launches first salvo in Pfizer fight, alleging ex-CEO, CFO were pressured to flip
7 months ago
R&D
Former Pfizer CEO and CFO flip on activist and say they now support company
7 months ago
People
Pharma
Covering obesity drugs could cost Medicare $35B by 2034, CBO says
7 months ago
FDA+
Pfizer's former top executives pitched changes to board as part of activist's plan
7 months ago
People
Pharma
BARDA doles out $72M to Sanofi, GSK and CSL for bird flu vaccine supply
7 months ago
Pharma
FDA+
J&J discontinues mid-stage dengue study, citing deprioritization of communicable disease work
7 months ago
R&D
Pharma
Exclusive: Relay Therapeutics cuts another 10% of company, citing continued streamlining efforts
8 months ago
People
R&D
First page
Previous page
5
6
7
8
9
10
11
Next page
Last page
Confirm Profile
Full Name
Email
Company
Job Title
{@!--CONSENT--!@}
Submit